HURA earnings analysis
What we found in HURA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so quarterly operating trends cannot be assessed. Controls were deemed effective as of June 30, 2026, and no material legal proceedings or control changes were reported. The principal new disclosure is a CEO Rule 10b5-1 plan covering up to 1,500,000 shares, creating a potential insider-selling overhang.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls Remained Effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control that materially affected or were reasonably likely to materially affect reporting.
- No Material Legal Proceedings
- No material legal matters or claims were reported as of the date of the Quarterly Report; the filing states the company was not party to any such matters.
- CEO Trading Plan Disclosed
- The CEO adopted a Rule 10b5-1 trading plan on June 4, 2026, allowing potential sales of up to 1,500,000 option shares and other common shares, subject to the plan’s conditions.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Potential Insider-Sale Overhang
- The CEO’s June 4, 2026 Rule 10b5-1 plan permits potential sales of up to 1,500,000 option shares and other common shares, which could increase market supply and create an overhang.
- Limited Quarterly Financial Disclosure
- The filing provides no updated quantitative revenue, EPS, cash-flow, balance-sheet, or segment results in the provided text, limiting assessment of operating performance for the quarter ended June 30, 2026.
- No Risk-Factor Update
- The company stated that there were no material changes to the risk factors in its December 31, 2025 Form 10-K filed March 31, 2026, or its March 31, 2026 Form 10-Q filed April 14, 2026; consequently, previously disclosed risks remain applicable.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue or EPS outlook; numeric guidance was not provided.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- TuHURA Biosciences reported a continued trend of no revenue generation in Q1 2026, with a diluted EPS of -0.13, consistent with the previous quarter but reflecting worsening net losses of $7.5 million compared to $6.7…
- 10-K · April 30, 2026
- TuHURA Biosciences reported total net losses of $30.1 million for the year ending December 31, 2025, a significant increase from the $21.7 million loss in 2024. The company has not generated any revenue, continuing to…
- 10-K · March 31, 2026
- TuHURA is a clinical‑stage immuno‑oncology company that initiated a Phase 3 SPA‑backed trial for IFx‑2.0 in June 2025 and completed the acquisition of Kineta on June 30, 2025, adding TBS‑2025 to its pipeline. The filing…
- 10-Q · November 14, 2025
- TuHURA reported no product revenue and continues to operate as a clinical-stage biopharma. Q3 2025 showed a larger GAAP net loss of $7,102,455 (vs $5,579,117 in Q3 2024) and quarter EPS of $(0.14); cash fell to $2.70M…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HURA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever